GSK Invests £400 Million to Reshape UK R&D Footprint, With More Than 1,000 Scientists Moving to Cambridge

For large pharmaceutical companies, choosing a location for an R&D centre is not merely a real estate decision; it also affects how quickly scientists can access clinical settings, academic talent and partner companies. GSK has announced a restructuring of its UK R&D footprint, with plans to establish a new global flagship R&D centre at the Cambridge Biomedical Campus. The centre is expected to accommodate more than 1,000 scientists focused on oncology, respiratory diseases, liver diseases, vaccines and HIV research.

The new centre will span approximately 300,000 square feet and be located on Discovery Drive, with logistics and property developer Prologis responsible for its development. Cambridge Network disclosed that the overall plan covers three connected buildings: 2000, 3000 and 4000 Discovery Drive. Construction has begun on the first building, the second has received full planning permission, and the third has received conditional approval from the planning committee but is still awaiting formal permission.

The £400 million cited by GSK will not be invested entirely in the new Cambridge development; rather, it is the total for a series of UK facilities changes over the next three years. In addition to establishing the new Cambridge site, the company will upgrade its R&D laboratories in Ware, Hertfordshire, integrating drug development with commercial manufacturing scale-up capabilities. It will gradually exit its existing Stevenage R&D site, with employees expected to relocate in phases by 2029.

The Cambridge Biomedical Campus brings together research institutions, hospitals and biotech companies. GSK already participates in local collaborations involving translational immunology, metabolic science, immune ageing and data-driven research, and operates a clinical unit at Addenbrooke’s Hospital. Concentrating more research teams there is intended to shorten the distance between basic discovery, patient research and drug development. However, the company has not announced an exact date for the centre to become fully operational, nor has it specified how many of the more than 1,000 researchers will represent newly created positions.

The development aligns with an R&D acceleration strategy announced by GSK at the same time. The company currently has 62 clinical development assets, 19 of which have entered Phase 3, and has identified acceleration opportunities covering 18 indications across seven late-stage products, focused on oncology, respiratory diseases, liver diseases and vaccines. GSK has therefore raised the number of Phase 3 trials it expects to initiate in 2026 from the original 10 to more than 20.

The other side of expanding R&D is organisational and cost restructuring. GSK has launched a three-year “Accelerate Growth” programme targeting £1.9 billion in annual savings by 2029, with most of the funds to be reinvested in late-stage products, R&D and business development. In other words, the Cambridge centre is not an isolated campus investment, but part of a broader effort to increase R&D output through site consolidation, resource reallocation and faster clinical trials.

However, building new laboratories does not in itself guarantee success in drug development. Some buildings at the centre are still awaiting formal permission, and the relocation will take place over several years. Whether the R&D acceleration programme ultimately translates into faster trial recruitment, clear clinical benefits and regulatory outcomes will still depend on subsequent data from each candidate product, rather than the scale of the facilities.